KSGO 2025

PROGRAM

Scientific Program

Program

Scientific Program

Program at a Glance
Pre-Congress Workshop
Scientific Program
Invited Speakers

Scientific Program

Pre-Congress Workshop: April 24 (Thu)

Day 1: April 25 (Fri)

Day 2: April 26 (Sat)

Hall A

Hall B

Hall C

Hall D

Hall E

08:30 - 09:30	Best Oral Presentation	Hall A/B/C
Chair(s)	Sooyoung Hur (The Catholic University of Korea), Jeong-Won Lee (Sungkyunkwan University)
08:30-08:40	Impact of neoadjuvant chemotherapy (NAC) combined with durvalumab and tremelimumab on the tumour Immune microenvironment in advanced ovarian cancer: translational analyses from the TRU-D/KGOG 3046 study Junsik Park (Soonchunhyang University)
08:40-08:45	Designated discussion Taehun Kim (Seoul National University)
08:45-08:55	Integrative spatial and transcriptomic profiling reveals novel prognostic clusters in cervical cancer Jong Mi Kim (Kyungpook National University)
08:55-09:00	Designated discussion Eun Bi Jang (Konkuk University)
09:00-09:10	A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC) Yong Jae Lee (Yonsei University)
09:10-09:15	Designated discussion Soo Hyun Oh (Gachon University)
09:15-09:25	Utility of the CA125 KELIM in for predicting the Benefit of from HIPEC in patients with advanced ovarian cancer: Pooled analysis of Individual data from KGOG3042 and KOV-HIPEC-01 Hyun-Woong Cho (Korea University)
09:25-09:30	Designated discussion Soo Young Jeong (Hallym University)

09:30-10:00	Opening Ceremony	Hall A/B/C
09:30-10:00	Welcome Remark Jae-Kwan Lee (President of KSGO)
	2025 - 2026 KSGO Board of Directors
	2025 New Gynecologic Oncologist of KSGO Eun Bi Jang (Konkuk University), Jimin Lee (Ajou University), Mia Park (Chungnam National University), Ji Hyun Lee (Yonsei University)
	KSGO Achievement Award Jae-Weon Kim (Past President of KSGO), Hee Seung Kim (Past Secretary General of KSGO)
	Introduction of KSGO International Conference 2025 Suk-Joon Chang (Chair of Scientific Program Committee)

10:00-11:30	Scientific Session I (Ovarian Cancer)	Hall A
Chair(s)	Young Tae Kim (Yonsei University), Yoichi Kobayashi (Kyorin University)
10:00-10:20	Role of secondary cytoreductive surgery for recurrent ovarian cancer in the era of PARPi Christina Fotopoulou (Imperial College London)
10:20-10:25	Designated discussion Hyeong In Ha (NHIC Ilsan Hospital)
10:25-10:30	Floor discussion
10:30-10:50	Updated ovarian cancer trials in China Rongyu Zang (Zhongshan Hospital)
10:50-10:55	Designated discussion Shin-Wha Lee (University of Ulsan)
10:55-11:00	Floor discussion
11:00-11:20	Future of clinical trials and translational research Jung-Min Lee (National Cancer Institute)
11:20-11:25	Designated discussion Sung Jong Lee (The Catholic University of Korea)
11:25-11:30	Floor discussion

12:20-12:50	Industry Session I - BORYUNG	Hall A
Chair(s)	Taek Sang Lee (Seoul National University)
12:20-12:40	Latest knowledge of 2nd generation G-CSF in gynecological cancer (Neulasta) Joseph Noh (Seoul National University)
12:40-12:50	Floor discusssion

13:00-14:00	Collaborative Session: Current Status of Gynecologic Cancer Treatment in China (CSGO)	Hall A
Chair(s)	Beihua Kong (Qilu Hospital of Shandong University), Guonan Zhang (Sichuan Cancer Hospital)
13:00-13:15	The laparoscopic surgery for early stage of cervical cancer: What is the future? Yang Xiang (PUMC Hospital)
13:15-13:20	Designated discussion Seung Hyuk Shim (Konkuk University)
13:20-13:35	The fertility sparing treatment for endometrium cancer in China Jianliu Wang (Peking University People's Hospital)
13:35-13:40	Designated discussion Jeong-Yeol Park (University of Ulsan)
13:40-13:55	Ovarian cancer trials in China Rongyu Zang (Zhongshan Tumor Hospital, Shanghai)
13:55-14:00	Designated discussion Jae Yun Song (Korea University)

14:20-17:20	Live Surgery-Ovarian Cancer	Hall A
Chair(s)	Suk-Joon Chang (Ajou University), Christina Fotopoulou (Imperial College London), Yoo-Young Lee (Sungkyunkwan University)
	Primary cytoreductive surgery for ovarian cancer Phillip Harter (Ev. Kliniken Essen-Mitte)
14:20-17:20	Interval cytoreductive surgery for ovarian cancer Sang Yoon Park (National Cancer Center)
	Robot hybrid cytoreductive surgery Myong Cheol Lim (National Cancer Center)

Korean Society of Gynecologic Oncology

Address. 36 Gangnam-daero 132-gil, Gangnam District, Seoul, Republic of Koera
Tel. +82 2 512 5915, 0044 ｜ Email. gyncancer@gyncancer.or.kr
President, Jae-Kwan Lee ｜ Business license number: 211-82-60962
COPYRIGHTⓒ KSGO2025. All Rights Reserved.

KSGO International Conference 2025 Secretariat: Double-You Plan

Address. 7, Achiul-gil 22beon-gil, Guri-si, Gyeonggi-do, Republic of Korea
Tel : 82-2-6959-5624 Fax : 82-2-6959-9379 E-mail : ksgo2025secretariat@gmail.com

11:00-12:00	Collaborative Session: Current Status of Gynecologic Cancer Treatment in Japan (JSGO)	Hall B
Chair(s)	Aikou Okamoto (Jikei University), Jae-Weon Kim (Seoul National University)
11:00-11:15	Cervical cancer Hideki Tokunaga (Tohoku University)
11:15-11:20	Designated discussion Eun Ji Nam (Yonsei University)
11:20-11:35	Endometrial cancer Tohru Morisada (Kyorin University)
11:35-11:40	Designated discussion Banghyun Lee (Inha University)
11:40-11:55	Ovarian cancer Tsukasa Baba (Iwate Medical University)
11:55-12:00	Designated discussion Sang Hun Lee (University of Ulsan)

13:00-13:40	Mini-Oral I	Hall C
Chair(s)	Yong Beom Kim (Seoul National University), Dong Choon Park (The Catholic University of Korea)
13:00-13:04	Characterization of humanized mouse model for evaluating immunotherapy in ovarian cancer Sung Wan Kang (Asan Medical Center)
13:04-13:08	Discussion
13:08-13:12	Is consolidation therapy effective in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment? Eun Bi Jang (Konkuk University Medical Center)
13:12-13:16	Discussion
13:16-13:20	Microbial metabolites control self-renewal and precancerous progression of human cervical stem cells Hee Yeun Yoon (Kyungpook National University)
13:20-13:24	Discussion
13:24-13:28	Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: a phase III, double-blind, randomized study Hee Seung Kim (Seoul National University)
13:28-13:32	Discussion
13:32-13:36	Clinical impact of first-line maintenance therapy agents on survival outcomes in ovarian cancer patients stratified by homologous recombination status Young Joo Lee (Kyung Hee University)
13:36-13:40	Discussion

15:00-17:05	Collaborative Session: AOGIN	Hall C
Chair(s)	Part 1: Current Issues in Cervical Cancer Screening and Management - Yong-Man Kim (University of Ulsan)
15:00-15:20	Cervical cancer screening based on HPV test Shin-Wha Lee (University of Ulsan)
15:20-15:40	Implementation of primary HPV screening and self-sampling in Thailand Wichai Termrungruanglert (Chulalongkorn University)
15:40-16:00	The role of extended genotyping in cervical cancer elimination Tessa Riandini (Becton, Dickinson and Company)
16:00-16:10	Discussion
Chair(s)	Part 2: Position Statement and Campaign of International Societies - Young-Tak Kim (CHA University)
16:10-16:35	Benefits for Asian societies in IPVC 2025 and AI in cervical cancer screening and management Siriwan Tangjitgamol (Vajira Hospital)
16:35-16:55	Global cervical cancer awareness campaign Hyo Sook Bae (For C Campaign.org)
16:55-17:05	Discussion

13:40-14:30	E-poster Session		Hall D
Chair(s)	Line 1 - Dae Hoon Jeong (Inje University)	Line 2 - Gun Oh Chong (Kyungpook National University)	Line 3 -Eun-Ju Lee (Chung-Ang University)
13:40-13:45	Effects of metabolic risk score on treatment decision for endometrial cancer: establishment of a machine learning-based predictive model for survival Jingyuan Wang (Peking University)	Does HRD score predict response and survival outcomes to platinum-based neoadjuvant chemotherapy? Uisuk Kim (National Cancer Center)	Oregovomab in combination with non-platinum chemotherapy for the treatment of PARP inhibitor- and platinum-resistant ovarian cancer: a two-cohort, single-arm phase 2 study (OPERA/KGOG3065/APGOT-OV6) Junsik Park (Soonchunhyang University)
13:45-13:47	Discussion	Discussion	Discussion
13:47-13:52	vNOTES hysterectomy with sentinel node dissection Edvard Berg (Bashkir State Medical University)	Prognosis of patients who become pregnancy after achieving a complete response with fertility-sparing treatment in early endometrial cancer: Gynecologic oncology research investigators coLLaborAtion study (GORILLA-3001) A Jin Lee (Ilsan Cha Hospital)	Outcomes of laparoscopic resection for pelvic recurrence of endometrial cancer: A single-center retrospective study Risako Ozawa (Cancer Institute Hospital of JFCR)
13:52-13:54	Discussion	Discussion	Discussion
13:54-13:59	Surgical indications for residual and recurrent cervical cancer after radiation therapy Mayumi Kamata (Cancer Institute Hospital of JFCR)	Prognostic impact of primary surgery in human papillomavirus-independent, advanced or metastatic endocervical adenocarcinoma: A bi-institutional retrospective study Jun-Hyeong Seo (Sungkyunkwan University)	Landscape of genomic alterations and clinical outcomes in low-grade serous ovarian cancer in Korea Ji Hyun Kim (National Cancer Center)
13:59-14:01	Discussion	Discussion	Discussion
14:01-14:06	Challenges facing female gynecologic oncology professionals in their career development: Results from the survey of Asian countries Ga Won Yim (Dongguk University Medical Center)	Postoperative early morbidity and mortality outcomes of primary and interval cytoreductive surgery for advanced epithelial ovarian cancer; A Korean gynecologic oncologic group (KGOG 4005/4006) Heon Jong Yoo (Chung-Ang University)	Value of systematic lymphadenectomy in early stage, high grade epithelial ovarian cancer, in the era of modern imaging Minah Ha (Te Whatu Ora Health New Zealand)
14:06-14:08	Discussion	Discussion	Discussion
14:08-14:13	Monocytes as potential predictors of immune-related adverse events (irAEs) in cancer patients receiving immune checkpoint inhibitors Ayumi Shikama (University of Tsukuba)	A domestic exchange program for gynecologic oncology doctors in Japan Hiroko Matsumiya (Hokkaido University Hospital)	Clinical significance of claudin18 in gastric adenocarcinoma of the cervix Fumimasa Osone (The Jikei University Hospital)
14:13-14:15	Discussion	Discussion	Discussion
14:15-14:20	Clinical features’ differences between CA-125 and RECIST progression in ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors Yana Ma (Qilu hospital of Shandong University)	Hyperthermia-Induced sensitization of cisplatin-resistant ovarian cancer cells: A potential strategy for overcoming drug resistance Joo-Hyuk Son (Ajou University)	Survival outcomes of postoperative chemotherapy versus concurrent chemoradiotherapy followed by chemotherapy in advanced endometrial cancer Aeran Seol (Seoul National University)
14:20-14:22	Discussion	Discussion	Discussion
14:22-14:27	Impact of primary radical surgery on survival outcomes in patients with locally advanced HPV-independent endocervical adenocarcinoma Hyunji Lim (Seoul National University)	GLDC promotes cisplatin resistance of ovarian cancer cells by enhancing ROS-driven mitochondrial fission Seungmee Lee (Keimyung University)	Pattern of care study for radiotherapy of recurrent ovarian cancer patients among gynecologic and radiation oncologists in Korea Bo Ra Kim (Ewha Womans University Medical Center)
14:27-14:29	Discussion	Discussion	Discussion

08:30-17:20	Surgical Film Screening	Hall E
SF-01	Intraoperative mesenteric lymphatic mapping to prevent chylous leakage: A case report	Chowon Park (CHA University)
SF-02	A comprehensive guide to vNOTES pelvic lymphadenectomy in early-stage endometrial cancer	Sujin Lee (Seoul ST. Mary’s Hospital)
SF-03	How to use the indocyanine green after sentinel lymph node biopsy during staging surgery	Won Moo Lee (Hanyang University)
SF-04	Robotic primary staging surgery in stage IIIA ovarian cancer	Seon-Mi Lee (Korea University Anam Hospital)
SF-05	Early experience of DV5 system for endometrial cancer using lower pelvic port placement	Seongmin Kim (Korea University Anam Hospital)

12:20-12:50	Industry Session II - MSD	Hall B
Chair(s)	Sang Wun Kim (Yonsei University)
12:20-12:40	Breaking endometrial cancer, building a patient's life: The role of pembrolizumab in both pMMR and dMMR (KEYNOTE-868/NRG-GY018) Yoo-Young Lee (Sungkyunkwan University)
12:40-12:50	Floor discusssion

12:20-12:50	Industry Session III - HK inno.N	Hall C
Chair(s)	Sokbom Kang (National Cancer Center)
12:20-12:40	The optimal treatment strategy for front-line ovarian cancer management Hyung Joon Yoon (Pusan National University)
12:40-12:50	Floor discusssion

08:00-08:40	Industry Session VII - Chong Kun Dang	Hall A
Chair(s)	Yong Beom Kim (Seoul National University)
08:00-08:30	New insight into strategies used to long-acting G-CSF for prevention of neutropenia Jeong-Yeol Park (University of Ulsan)
08:30-80:40	Floor discussion

09:30-11:30	Scientific Session II (Endometrium)	Hall A
Chair(s)	Byoung-Gie Kim (Sungkyunkwan University), Sang Hoon Kwon (Keimyung University)
09:30-09:50	Role of adjuvant therapy in early-stage endometrial cancer Philipp Harter (Ev. Kliniken Essen-Mitte)
09:50-09:55	Designated discussion Yung-Taek Ouh (Korea University)
09:55-10:00	Floor discussion
10:00-10:20	Innovations in molecular subtyping for precision medicine Jung-Yun Lee (Yonsei University)
10:20-10:25	Designated discussion Angela Cho (Jeju National University)
10:25-10:30	Floor discussion
10:30-10:50	Importance of follow-up of patients with uterine corpus cancer from the perspective of cardio-oncology Yoichi Kobayashi (Kyorin University)
10:50-10:55	Designated discussion Yu-Jin Koo (Yeungnam University)
10:55-11:00	Floor discussion
11:00-11:20	Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without Olaparib in endometrial cancer: Biomarkers, histological heterogeneity, baseline circulating tumor DNA levels, and efficacy in the DUO-E mismatch repair proficient subpopulation Jae-Weon Kim (Seoul National University)
11:20-11:25	Designated discussion Jin Hwa Hong (Korea University)
11:25-11:30	Floor discussion

11:50-12:20	Industry Session IV - GSK	Hall A
Chair(s)	Dae-Yeon Kim (University of Ulsan)
11:50-12:10	Illuminating advances: Transformative role of dostarlimab in advanced/recurrent endometrial cancer treatment Hee-Seung Kim (Seoul National University)
12:10-12:20	Floor discussion

12:50-14:20	Tumor Board: Multinational Tumor Board on Gynecologic Cancer: Exploring Treatment Landscapes	Hall A
Chair(s)	Yoo-Young Lee (Sungkyunkwan University)
Panel(s)	Siriwan Tangjitgamol (Vajira Hospital) Won Kyung Cho (Sungkyunkwan University) Tricia Dewi Angggraeni (Universitas Indonesia) Hiroyuki Kanao (Cancer Institute Hospital) Jen-Ruei Chen (MacKay Memorial Hospital) Yang Xiang (PUMC Hospital)

14:40-16:10	Debate Session	Hall A
Chair(s)	Jeong-Yeol Park (University of Ulsan)
Optimal surgical approach for early-stage cervical cancer
14:40-14:52	Favor minimally invasive surgery Yang Xiang (PUMC Hospital)
14:52-15:04	Favor open surgery Philipp Harter (Ev. Kliniken Essen-Mitte)
15:04-15:10	Discussion Seung Hyuk Shim (Konkuk University)
How to improve survival outcome in locally advanced cervical cancer
15:10-15:22	Favor addition of neoadjuvant chemotherapy or immune check point inhibitor to CCRT Christina Fotopoulou (Imperial College London)
15:22-15:34	Favor addition of debulking surgery to CCRT Ju-Won Roh (CHA University)
15:34-15:40	Discussion Sunmin Park (Korea University)
Optimal management of recurrent cervical cancer in irradiated pelvis
15:40-15:52	Favor surgical management including pelvic exenteration Hiroyuki Kanao (Cancer Institute Hospital)
15:52-16:04	Favor non-surgical management Jen-Ruei Chen (MacKay Memorial Hospital)
16:04-16:10	Discussion Hee Seung Kim (Seoul National University)

09:30-10:30	Collaborative Session: Current Status of Gynecologic Cancer Treatment in Thailand (TGCS)	Hall B
Chair(s)	Perapong Inthasorn (Mahidol University), Rakchai Buhachat (Prince of Songkhla University)
09:30-09:45	Endometrial cancer Atthapon Jaishuen (Mahidol University)
09:45-09:50	Designated discussion Seongmin Kim (Korea University)
09:50-10:05	Ovarian cancer Kamaitorn Tientong (Rajavithi Hospital)
10:05-10:10	Designated discussion Yoon Hee Lee (Kyungpook National University)
10:10-10:25	Cervical cancer Panwad Ratanasrithong (National Cancer Institute of Thailand)
10:25-10:30	Designated discussion Seungho Lee (Gachon University)

10:30-11:30	Collaborative Session: Current Status of Gynecologic Cancer Treatment in Taiwan (TAGO)	Hall B
Chair(s)	Cheng-Chang Chang (China Medical University Hospital), Kung-Liahng Wang (Mackay Memorial Hospital)
10:30-10:45	Focusing on the recent progress of the three major gynecological cancers from a clinical perspective in Taiwan Peng-Hui Wang (Taipei Veterans General Hospital)
10:45-10:50	Designated discussion Won Moo Lee (Hanyang University)
10:50-11:05	Experience sharing about hyperthermic intraperitoneal chemotherapy for ovarian, fallopian tubal and primary peritoneal cancers in a tertiary referral medical center in Taiwan Jen-Ruei Chen (MacKay Memorial Hospital)
11:05-11:10	Designated discussion Sanghoon Lee (Korea University)
11:10-11:25	Fallopian tube organoids: A novel approach for the discovery of early copy number alterations of high-grade serous ovarian cancer Hung-Cheng Lai (Taipei Medical University)
11:25-11:30	Designated discussion Eun Jung Yang (Soonchunhyang University)

11:50-12:20	Industry Session V - Takeda	Hall B
Chair(s)	Jae-Weon Kim (Seoul National University)
11:50-12:10	Exploring optimal PARP inhibitor treatment in advanced ovarian cancer Bradley Monk (Florida Cancer Specialists and Research Institute)
12:10-12:20	Floor discussion

08:30-09:30	JGO Workshop: Appropriate Use of AI in Writing and Reviewing Scientific Papers	Hall C
Chair(s)	Siriwan Tangjitgamol (Vajira Hospital), Hidemichi Watari (Hokkaido University)
08:30-08:50	AI-empowered manuscript writing Yusuke Kobayashi (University of Tsukuba)
08:50-09:10	Case study: AI application Dong Hoon Suh (Seoul National University)
09:10-09:30	Q&A

10:00-10:40	Mini-Oral II	Hall C
Chair(s)	Seob Jeon (Soonchunhyang University), Chul Min Park (Jeju National University)
10:00-10:04	Intratumor microbiome-derived butyrate facilitates progestin resistance by inducing ferroptosis in endometrial cancer Xingchen Li (Peking University)
10:04-10:08	Discussion
10:08-10:12	Survival outcomes of PCS vs. ICS in advanced ovarian cancer according to institutional criteria during the TRUST trial enrollment period Jae Kyung Bae (National Cancer Center)
10:12-10:16	Discussion
10:16-10:20	Histopathologic validation of 2023 FIGO stage IA1–IIIC2 endometrial carcinoma: A retrospective analysis of two tertiary centers in South Korea and Taiwan Myeong-Seon Kim (Chung-Ang University)
10:20-10:24	Discussion
10:24-10:28	Updates on prospective multi-institutional phase III trial of standard of care therapy with or without stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC, KGOG 3064/KROG 2204 Sangjoon Park (Yonsei Cancer Center)
10:28-10:32	Discussion
10:32-10:36	The Forkhead box protein A1 gene exhibits oncogenic properties in ovarian cancer and can serve as a diagnostic biomarker Eunjung Yang (Soonchunhyang University)
10:36-10:40	Discussion

12:50-14:20	Collaborative session: KGOG - For the Glory of KGOG and KSGO	Hall B
Chair(s)	Jae Hoon Kim (Yonsei University)
12:50-13:00	Beginning and past of KGOG: Foundations of progress Yong-Man Kim (University of Ulsan)
13:00-13:10	KGOG Today: Advancing gynecologic oncology Dae-Yeon Kim (University of Ulsan)
13:10-13:20	Cervical cancer innovations: KGOG-led studies and outcomes Sang Wun Kim (Yonsei University)
13:20-13:30	Endometrial cancer insights: KGOG-led research contributions Jeong-Yeol Park (University of Ulsan)
13:30-13:40	Ovarian cancer breakthroughs: Spotlight on KGOG-led studies Chel Hun Choi (Sungkyunkwan University)
13:40-13:50	Overview of the 400X protocol: Insights from the surgery and DDT committee Eun-Ju Lee (Chung-Ang University)
13:50-14:00	Collaborating for progress: KGOG’s role in NRG studies Min Kyu Kim (Sungkyunkwan University)
14:00-14:10	Expanding horizons: KGOG's participation in GOG-partners research Jae Yun Song (Korea University)
14:10-14:20	Global collaboration in gynecologic Oncology: KGOG in ENGOT, JGOG, and EAGOT initiatives Min Chul Choi (University of Ulsan)

14:40-16:10	Collaborative Session: KGCR - Innovations in Gynecological Cancer Translational Research: Current Trends and Future Directions	Hall B
Chair(s)	Yoo-Young Lee (Sungkyunkwan University), Yusuke Kobayashi (University of Tsukuba)
14:40-15:00	Translational research approaches utilizing PDX and PDO models in gynecologic cancer Jeong-Won Lee (Sungkyunkwan University)
15:00-15:20	Development of novel personalized medicine for ovarian clear cell carcinoma Shogo Shigeta (Tohoku University)
15:20-15:40	Therapy of drug resistant ovarian cancer Jaeho Kim (Pusan National University)
15:40-16:00	New findings of basic research on PARP and functional analysis of SLFN11 related to therapeutic effect of PARP inhibitors Junko Murai (Ehime University)
16:00-16:10	Discussion

10:40-11:20	Mini-Oral III	Hall C
Chair(s)	Ki Hyung Kim (Pusan National University), Ju-Won Roh (CHA University)
10:40-10:44	Evaluation for risk factors against expectant management in cervical intraepithelial neoplasia: A multicenter real-world cohort study Heekyoung Song (The Catholic University of Korea)
10:44-10:48	Discussion
10:48-10:52	Survival implications of sarcopenia in epithelial ovarian cancer patients undergoing bowel surgery Jihye Kim (Chung-Ang University Hospital)
10:52-10:56	Discussion
10:56-11:00	Type-specific risk of high-risk human papillomavirus (HR-HPV) for cervical intraepithelial neoplasia 2 or worse in HR-HPV positive women with mildly abnormal cervical cytology Min-Jeong Kim (Cha University)
11:00-11:04	Discussion
11:04-11:08	Effectiveness of HPV vaccination across age groups: The Korean HPV cohort study Sanha Lee (The Catholic University of Korea)
11:08-11:12	Discussion
11:12-11:16	The value of the naples prognostic score as a predictor of cancer progression in cervical cancer Seon Mi Lee (Korea University)
11:16-11:20	Discussion

11:50-12:20	Industry Session VI - Roche Diagnostics	Hall C
Chair(s)	Jae Hong No (Seoul National University)
11:50-12:10	The new paradigm (CINtec PLUS): Dual stain triage for cervical cancer screening Heekyoung Song (The Catholic University of Korea)
12:10-12:20	Floor discussion

12:50-14:20	Young Investigator Session	Hall C
Chair(s)	Sunghoon Kim (Yonsei University), Myong Cheol Lim (National Cancer Center)
12:50-12:57	Clinical application of circulating tumor DNA for tumor profiling and monitoring in high-grade serous ovarian cancer Se Ik Kim (Seoul National University)
12:57-13:00	Discussion
13:00-13:07	A multicenter study of laparoscopic versus laparotomic surgery in the treatment of stage I adult granulosa cell and sertoli-leydig cell tumors: (LARGES): Gynecologic oncology research investigators coLLaborAtion study (GORILLA-3005) Jimin Lee (Ajou University)
13:07-13:10	Discussion
13:10-13:17	Clinicopathological characters, immunotherapy efficacy and oncological outcomes of gastric-type endocervical adenocarcinoma Ming Du (Peking Union Medical College Hospital)
13:17-13:20	Discussion
13:20-13:27	Is it safe to reserve uterus after live-birth following fertility-sparing treatment of endometrial cancer and atypical hyperplasia: A long-term retrospective cohort study Yiqin Wang (Peking University People's Hospital)
13:27-13:30	Discussion
13:30-13:37	Cell-free and concentrated ascites reinfusion therapy (CART) shows enhanced efficacy in gynecological cancer patients: A post-marketing surveillance study Nami Tamura (Juntendo University)
13:37-13:40	Discussion
13:40-13:47	Early detection of malignancy, and identify key molecules involved in ovarian tumor metastasis using plasma and saliva-derived exosomes in 90 cases Yuichi Shoburu (The University of Tokyo)
13:47-13:50	Discussion
13:50-13:57	When pathology diverges: Investigating discrepancies between original and review diagnoses in cervical cancer and precancer Nida Jareemit (Mahidol University)
13:57-14:00	Discussion
14:00-14:07	Prevalence and factors associated with discrepancies between original and review pathology examinations in referral cases of premalignant and malignant endometrial lesions Jira-Bhadhra WongwathanvikromI (Mahidol University)
14:07-14:10	Discussion
14:10-14:17	The role of radical mastectomy on breast metastasis from ovarian high grade serous carcinoma origin: A rare case report Gerald Sebastian Davis (Dr. Soetomo General Academic Hospital)
14:17-14:20	Discussion

14:40-16:10	Nursing Session (Kor.)	Hall C
Chair(s)	Young Soo Chu (Korea University Anam Hospital), Woong Ju (Ewha Womans University)
14:40-14:55	The latest treatment for gynecologic cancer: Immuno-oncologic drug Nam Kyeong Kim (Korea University)
14:55-15:00	Floor discussion
15:00-15:15	Management of immuno-oncologic drug side effects Joo Hyun Kim (Samsung Medical Center)
15:15-15:20	Floor discussion
15:20-15:35	Radiation therapy and side effect management in gynecologic cancer patients Hye Sung Moon (Ewha Wonams University Mokdong Hospital)
15:35-15:40	Floor discussion
15:40-15:55	Pathologic and genetic testing in gynecologic cancer patients Soo Hyun Oh (Gachon University)
15:55-16:00	Floor discussion

08:30-16:10	E-Poster Exhibition	Hall D
PE-01	NIR-II fluorescence imaging based on Trop-2-targeting peptide guides precise resection of abdominal metastases from ovarian cancer	Chengxi LI (Xiamen University)
PE-02	Development of a blood cell analysis-based AI model for early detection of ovarian cancer (Withdrawal)	Se Ik Kim (Seoul National University Hospital)
PE-03	Prevalence of homologous recombination deficiency in Korean patients with epithelial ovarian cancer	Junhwan Kim (National Cancer Center)
PE-04	Clinical and molecular characteristics of patients with high-grade serous ovarian cancer recurring on PARP inhibitors	Hyun Park (CHA Bundang Medical Center)
PE-05	Mortality rate changes related to trends in the use of neoadjuvant chemotherapy in ovarian cancer in south korea: an analysis using national cancer registry data	Jun-Hyeong Seo (Samsung Medical Center)
PE-06	Screening of germline variants using tumor multigene panel in gynecological cancer (Withdrawal)	Kidong Kim (Seoul National University Bundang Hospital)
PE-07	Drug repurposing of biguanides: exploring the anti-cancer effects of phenformin and metformin in epithelial ovarian cancer	Jihye Kim (Chung-Ang University Hospital)
PE-08	Genomic analysis of PARP inhibitor response in high-grade serous ovarian cancer: Insights from whole genome sequencing (Withdrawal)	Ok-Ju Kang (Ulsan University Hospital)
PE-09	The gene expression signature of niraparib treatment in HRP ovarian cancer cells	Zhong Zheng (Fudan University Shanghai Cancer Center)
PE-10	The role of Gonadotropin-releasing hormone 2 in epithelial ovarian cancer	Eun-Ju Lee (Chung-Ang University Hospital)
PE-11	Comprehensive analysis of germline variants and clonal hematopoiesis in Ovarian Cancer patients using whole exome sequencing	Hye-Lim Cho (Incheon National University)
PE-12	cfDNA fragmentation signatures and a novel framework for epigenome-dependent analysis: Potential application in HRD and signature 3 (Withdrawal)	Yoo-Na Kim (Harvard Medical School)
PE-13	Development and validation of a blood-based high-Specificity PCR algorithm for diagnosis of ovarian cancer (Withdrawal)	Se Ik Kim (Seoul National University Hospital)
PE-14	Development of a next generation sequencing cancer panel-based homologous recombination deficiency test in epithelial ovarian cancer (Withdrawal)	Se Ik Kim (Seoul National University Hospital)
PE-15	Clinical and genetic predictive factors of PARP inhibitor efficacy in advanced or recurrent ovarian cancer	In Sun Hwang (Seoul ST. Mary’s Hospital)
PE-16	Preoperative MRI metrics as predictor of progression-free survival in epithelial ovarian cancer	Heekyoung Song (Incheon ST. Mary’s Hospital)
PE-17	Metabolomic and transcriptomic analyses identify metabolic alterations and immune suppression in ovarian cancer	Maiko Yamaguchi (National Cancer Center Research Institute)
PE-19	Postoperative systemic immune-inflammatory index (SII) as a prognostic factor in Epithelial ovarian cancer	Young Eun Chung (Samsung Medical Center)
PE-20	A retrospective study of 11 cases from a single institution: malignant transformation arising from mature cystic teratoma	Minseong Choi (Inje University Haeundae Paik Hospital)
PE-21	Optimizing hIPEC protocols: Preventive approaches for cisplatin-Induced AKI in ovarian cancer	Jimin Lee (Ajou University Medical Center)
PE-22	The association between location of BRCA mutation and efficacy of PARP inhibitor as a frontline maintenance therapy in advanced epithelial ovarian cancer	Ji Hyun Kim (National Cancer Center)
PE-23	Comparative efficacy of Olaparib and niraparib in maintenance therapy for brca-mutated epithelial ovarian cancer: A real-world survival analysis	Yae-Sol Kim (Seoul Asan Medical Center)
PE-24	Treatment results using PARP inhibitors for advanced ovarian cancer～From our hospital data～	Miseon Nakazawa (NTT Medical Center Sapporo)
PE-25	ESRP1-Mediated alternative splicing in ovarian cancer: Insights from RNA splicing analysis and evolutionary patterns in tumor cells	Xihan Liu (Qilu Hospital Shandong University)
PE-26	Clinical and survival outcomes of controlled suction technique with minimal spillage in the patients presented with huge ovarian cyst	Nam Kyeong Kim (Korea University Ansan Hospital)
PE-27	Maintenance of PARP inhibitor rechallenge plus Bevacizumab in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor (KGOG 3056/NIRVANA-R)	Hyun-Woong Cho (Korea University Guro Hospital)
PE-28	Survival outcomes and prognostic factors in advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer	Mohamad Nurfadli Senin (Ministry of Health)
PE-29	Study of fatty acids promoting lymphovascular space invasion in endometrial cancer through ITGB3-ICAM1-TRPV4 mediating mechanical crosstalk between cancer cells and endothelial cells	Jingyuan Wang (Peking University People's Hospital)
PE-30	Usefulness of droplet digital polymerase chain reaction (ddPCR) assay for POLE mutation in the molecular endometrial cancer staging system and comparison of survival prognosis with the 2009 FIGO Stage	Sung-Jong Lee (Seoul ST. Mary’s Hospital)
PE-31	The neutrophil-albumin index as a discriminative tool for distinguishing uterine leiomyosarcoma from uterine leiomyoma	Hyung Joon Yoon (Pusan National University Hospital)
PE-32	Endometrial cancer detected unusually after an ankle fracture secondary to severe anemia in an obese woman with heavy menstrual bleeding: A case report	Hyung Joon Yoon (Pusan National University Hospital)
PE-33	Evaluating offspring growth and behavioral development after maternal fertility-sparing treatment of early endometrial cancer or atypical endometrium hyperplasia: A multicentre observational study	Yifan Feng (Peking University People's Hospital)
PE-34	Usefulness of blood NGS tests in endometrial cancer	Eunhye Cho (Inje University Busan Paik Hospital)
PE-35	Metabolic syndrome combined with insulin resistance showed great predictive value in evaluating recurrence in patients with atypical endometrial hyperplasia and early endometrial cancer	Xingchen Li (Peking University People)
PE-36	Association between dietary inflammatory index and risk of endometrial cancer in the prostate, lung, colorectal, and ovarian cancer screening trial	Kun Song (Qilu Hospital, Shandong University)
PE-37	Effect of smoking status on endometrial cancer risk by menopausal status: A nationwide cohort study.	Sung Jong Lee (Seoul ST. Mary’s Hospital)
PE-38	High glucose promotes metastasis and stemness of endometrial cancer by regulating IGF2BP1-Mediated m6A methylation of CITED2 mRNA	Chengcheng Li (Peking University People's Hospital)
PE-39	SORBS3-β promotes ubiquitination and degradation of β-catenin to suppress lymph node metastasis in cervical cancer	Huating Sun (The First Affiliated Hospital of Soochow University)
PE-40	Molecular characterization of advanced endometrial cancer	Mi-Kyung Kim (Ewha Womans University Medical Center)
PE-41	The mechanism study of lipid metabolism disorder to promote lymphovascular space invasion in endometrial cancer by regulating PI3K/Akt axis mediated by ITGB3	Jingyuan Wang (Peking University People's Hospital)
PE-42	Different maintenance treatment regimens for recurrence after fertility sparing treatment in patients with endometrial cancer and atypical endometrial hyperplasia	Zerui Xiao (Peking University People' s Hospital)
PE-43	Precision molecular profiling of endometrial cancer: Evaluating ddPCR for POLE mutation detection	Yung-Taek Ouh (Korea University Ansan Hospital)
PE-44	Prognostic significance of Systemic immune-inflammation index (SII) in endometrial cancer: Highlighting the predictive value of post-chemotherapy SII for survival outcomes	Seongyun Lim (Samsung Medical Center)
PE-45	Association between Estrogen receptor/Progesterone receptor Status and Risk Factors in Postmenopausal Women with Endometrioid Type Endometrial Cancer	Yongil Ji (Inje University Haeundae Paik Hospital)
PE-46	Predictive value of primary tumor SUVmax on 18F-fluro-2-deoxy-D-glucose positron emission tomography and computed tomography in patients undergoing fertility-sparing treatment for early endometrial cancer	Eun Bi Jang (Konkuk University Medical Center)
PE-47	Endometrial carcinosarcoma presenting as nonpuerperal uterine inversion in a 44-year-old virgin: a case report	Nam Kyeong Kim (Korea University Ansan Hospital)
PE-48	Bariatric surgery: A promising adjunct to fertility-sparing treatment in obese endometrial cancer patients	Jin Lai (Peking University People’s hospital)
PE-49	FOXA2-mediated recovery of PR expression: A molecular approach against PR-negative endometrial cancer	Jie Liu (Peking University)
PE-50	Immunotherapy and progestin therapy lead to different pathological responses and immune microenvironment as fertility-sparing strategies in MMRd endometrial cancer	Yiqin Wang (Peking University People)
PE-51	Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without Olaparib for endometrial cancer: Mismatch repair deficient and/or microsatellite instability-high subpopulation efficacy analyses from the DUO-E trial	Jae Weon Kim (Seoul National University Hospital)
PE-52	Preclinical evaluation for the efficacy of JPI-547, a dual inhibitor of PARP 1/2 and tankyrase 1/2, in endometrial cancer cell lines	Hyerim Eum (Seoul Asan Medical Center)
PE-53	Comparison on surgical outcomes by open, laparoscopy and robotic surgery in obese women with endometrial cancer	Thitisak Vanichpakorn (Prince of Songkla University)
PE-54	Fertility-preserving treatment of endometrial cancer and endometrial atypical hyperplasia for patients with metabolic abnormalities: Challenge or opportunity?	Jianliu Wang (Peking University People’ Hospital)
PE-55	Efficient and minimally invasive: Robotic SP®-Assisted VNOTES for endometrial cancer management	Gyul Jung (Seoul ST. Mary’s Hospital)
PE-56	Clinical efficacy of molecular classification for endometrial cancer: preliminary results from a single-center study	Seung Ho Kim (Hallym University Dongtan Sacred Heart Hospital)
PE-57	Corded and hyalinized endometrioid endometrial carcinoma: A rare case treated with robot-assisted surgery	Su Jeong Lee (Uijeongbu ST. Mary’s Hospital)
PE-58	Examination of the functions and mechanism of KCP in mediating paclitaxel resistance in cervical squamous carcinoma cells	Yue He (Beijing Obstetrics and Gynecology Hospital)
PE-59	ZBTB5 enhances the resistance of cervical cancer to paclitaxel by regulating BCL6	Yue He (Beijing Obstetrics and Gynecology Hospital)
PE-60	Establishment of a risk prediction model for predicting cervical lesions in HR-HPV positive women based on host six-gene methylation	Bin Li (Shaanxi Provincial People)
PE-61	Persistent inflammation and abnormal finding in physical exam: Surgical decisions in persistent high-risk HPV infections without HSIL results	Hyun Jin Choi (Chung-Ang University Hospital)
PE-62	The significance of HPV 18 in neuroendocrine carcinoma of the cervix The significance of HPV 18 in neuroendocrine carcinoma of the cervix (Withdrawal)	Se Ik Kim (Seoul National University Hospital)
PE-63	Association between underlying comorbidities and the risk of cervical cancer: A retrospective cohort study in the South Korea	Yongwook Kim (Incheon ST. Mary’s Hospital)
PE-64	Hematopoietic stem cell-containing autologous blood transfusion for bone marrow protection in patients with cervical cancer	Na Zhang (Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital)
PE-65	A comparative study of cervicovaginal microbiome in women with or without human papillomavirus infection.	Kavita Khoiwal (AIIMS Rishikesh)
PE-66	Excessive carbohydrate Intake associated with higher risk of cervical cancer in Korea : Korean national health and nutrition examination survey 2016-2021	Seon Mi Lee (Korea University Anam Hospital)
PE-67	The impact of physical activity on mortality among women with cervical cancer	Young Eun Chung (Samsung Medical Center)
PE-68	Cervical HPV prevalence and analysis of human leukocyte antigen among women with hematologic malignancies	Min Jin Jeong (Eunpyeong St. Mary’s Hospital)
PE-69	Kielin chordin protein as a biomarker predicting chemo-resistance in cervical cancer to paclitaxel	Chen Ji (Beijing Obstetrics and Gynecology Hospital)
PE-70	Prognostic analysis of patients with locally advanced cervical cancer undergoing radical hysterectomy	Yong Zhao (Qilu Hospital of Shandong University)
PE-71	Assessment of reproductive outcomes of patients with early-stage (IA1-IB1) cervical cancer after repeated conization versus single conization	Beihua Kong (Qilu Hospital of Shandong University)
PE-72	Risk factors for high-grade squamous intraepithelial lesion recurrence after the two-layer loop electrosurgical excision procedure in patients with positive endocervical, exocervical, and deep margins	In Sun Hwang (Seoul ST. Mary’s Hospital)
PE-73	Mixed neuroendocrine tumor of the cervix has a poorer prognosis than pure neuroendocrine tumor (NECXT) (Withdrawal)	Kidong Kim (Seoul National University Bundang Hospital)
PE-74	A case of cervical carcinoma with perforation of pyometra of the uterus	Kengo Hiranuma (JUNTENDO University)
PE-75	Results of treatment for FIGO stage I-II vulvar squamous cell carcinoma at Viet Nam National cancer Hospital.	Anh Nguyen (Vietnam National Cancer Hospital)
PE-76	Real-world efficacy and survival of PD-1/PD-L1 monoclonal antibody-based immunotherapy in cervical cancer.	Xinran Li (Peking Union Medical College Hospital)
PE-77	Sensitivity prediction to uterine artery interventional chemoembolization in locally advanced cervical cancer with MRI-based radiomics	Bin Li (Shaanxi Provincial People's Hospital)
PE-78	Assessment of preoperative ultrasound for predicting the feasibility of minimally invasive surgery in early-stage cervical cancer: A pilot study	Kyung Jin Eoh (Yongin Severance Hospital)
PE-79	Effect of using McCartney tube to reduce tumor spillage during minimally invasive radical hysterectomy for cervical cancer	Seongmin Kim (Korea University Anam Hospital)
PE-80	Comparative analysis of laparoscopic, robotic-assisted, and abdominal radical hysterectomy for early-stage cervical cancer: A 22-year retrospective study	Changmin Shin (Keimyung University Dongsan Medical Center)
PE-81	Silk-based nanoparticle for enhanced paclitaxel delivery and targeted anticancer therapy in cervical cancer	Jung Hwan Ahn (Wonju Severance Christian Hospital)
PE-82	Normalization of posttreatment squamous cell carcinoma antigen (SCC Ag) as a prognostic marker in patients with advanced cervical cancer treated with first-line bevacizumab–paclitaxel–cisplatin therapy	Haa-Na Song (Gyeongsang National University Hospital)
PE-83	Construction and validation of a prognostic prediction model for aggressive histotype endometrial carcinoma	Beihua Kong (Qilu Hospital of Shandong University)
PE-84	Marker discovery of serum circulating metabolites distinguishing CIN from normal for cervical cancer prevention	Eunjung Yang (Soonchunhyang University Hospital Cheonan)
PE-85	Prognostic impact of positive margins after LEEP in patients with cervical intraepithelial neoplasia	Changmin Shin (Keimyung University Dongsan Medical Center)
PE-86	Detection of microbial infections and antibiotic resistance within 90 minutes in urine and blood samples of symptomatic patients with paper-based electrochemical DNA biosensor	Kavita Khoiwal (AIIMS Rishikesh)
PE-87	Indocyanine green vs. methylene blue: A comparative study on sentinel lymph node detection in early-stage endometrial cancer	Rahima Nazarova (National Oncology Center)
PE-88	Changes of disease spectrum of malignant tumor of female reproductive system in Beijing Obstetrics and Gynecology Hospital in recent 60 years	Yue He (Beijing Obstetrics and Gynecology Hospital)
PE-89	Treatment of radiation-induced vaginal stenosis using the martius-symmonds flap	Ilnur Musin (Bashkir State Medical University)
PE-90	An international prospective comparative study on articulating laparoscopic instruments in benign adnexal gynecologic surgery	Young Eun Chung (Samsung Medical Center)
PE-91	Genomic and transcriptomic profiling of Lynch Syndrome patients with unaffected carrier status, premalignant lesion, and endometrial carcinoma	Yoo-Na Kim (Severance Hospital)
PE-92	Feasibility exploration of constructing a patient derived tumor tissue xenograft (PDX) model for malignant tumors of the female reproductive system in mice	Yue He (Beijing Obstetrics and Gynecology Hospital)
PE-93	A unique case of recurrent LCH involving the bilateral vulva	Na Zhang (Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital)
PE-94	Impact of gut microbiota on immune checkpoint inhibitor efficacy in gynaecological cancers	Hyun Jin Choi (Chung-Ang University Hospital)
PE-95	Radiofrequency ablation	Amartuvshin T1,2 TUMENJARGEL (Mongolia-Japan Teaching Hospital)
PE-96	Primary peritoneal carcinoma mimicking advanced ovarian cancer	Kyongjin Kim (Presbyterian Medical Center)
PE-97	Hysterectomy for benign gynecologic disease: A comparative study of articulating laparoscopic instruments and robot-assisted surgery in Korea and Taiwan	Jun-Hyeong Seo (Samsung Medical Center)
PE-98	Feasibility of laparoscopic hysterectomy using an articulating laparoscopic instrument: A prospective observational study	Jun-Hyeong Seo (Samsung Medical Center)
PE-99	Comparison of artisential and conventional laparoscopic instruments in hysterectomy for gynecologic cancers: A hybrid observational study on surgical outcomes, pain control, and oncologic safety	Seongyun Lim (Samsung Medical Center)
PE-100	Application of the whole-course management model in patients with endometrial cancer or atypical hyperplasia undergoing fertility preservation	Yuanyuan Liu (Peking University People's Hospital)
PE-101	Risk factors associated with residual lesions in subsequent hysterectomy after loop electrosurgical excision procedure	Minseong Choi (Inje University Haeundae Paik Hospital)
PE-102	The impact of ME1 expression on tumor progression and immunotherapy in ovarian cancer: a comprehensive analysis	Jiahui Wei (Beijing Obstetrics and Gynecology Hospital)
PE-103	A comprehensive mRNA-lncRNA signature predicts lymph node metastasis in cervical cancer patients	Jiahui Wei (Beijing Obstetrics and Gynecology Hospital)
PE-104	Unexpected premalignant and malignant lesion of endometrium and ovary in fertility workup	Suresh Kayastha (Kathmandu Cancer Center)
PE-105	Histology type profile of endometrial abnormalities: A five-year prevalence study	Insi Hidayatul Husna (Andalas University)
PE-106	Analysis of histology type from uterine cervix biopsy in padang: A five-year retrospective study	Wendy Armi (Faculty of Medicine, Andalas University)
PE-107	Pathological examination overview of uterine tumors indicative of uterine cancer : A five-year retrospective study	M. Fikri Ridha (Andalas University)
PE-108	Histology analysis of ovarian tumors: A five-year retrospective study in an Indonesian Regional Hospital	Kelsy Qoridisa (Andalas University)
PE-109	High P63 expression associated with better survival outcome in FIGO stage IIIC1p cervical cancer	Jiao Wang (Beijing Obstetrics and Gynecology Hospital)
PE-110	CASE report: Challenges in management of malignant mixed mullerian tumour	Kathy Kathy (University of Medicine -2 , Yangon)